Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus CIS PYRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus CIS PYRO.
CIS-MDP vs CIS-PYRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Cis-pyro is not a recognized pharmaceutical agent. No mechanisms data available.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
Not applicable: CIS-PYRO is a pyrophosphate-based radiopharmaceutical used in cardiac imaging, not a therapeutic drug. Standard adult dose: 555-1110 MBq (15-30 mCi) intravenously once.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: 6-8 hours (IV); prolonged in renal impairment (up to 30 hours in ESRD).
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Primarily renal excretion: 65-80% unchanged in urine; biliary/fecal excretion accounts for 15-25%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical